A. Grimaldi¹, G. Pascazio², M. Napolitano³

CMES-Computer Modeling in Engineering & Sciences, Vol.14, No.1, pp. 45-56, 2006, DOI:10.3970/cmes.2006.014.045

Abstract This paper provides a numerical method for solving two- and three-dimensional unsteady incompressible flows. The vorticity-velocity formulation of the Navier--Stokes equations is considered, employing the vorticity transport equation and a second-order Poisson equation for the velocity. Second-order-accurate centred finite differences on a staggered grid are used for the space discretization. The vorticity equation is discretized in time using a fully implicit three-level scheme. At each physical time level, a dual-time stepping technique is used to solve the coupled system of non linear algebraic equations by various efficient relaxation schemes. Steady flows are computed by dropping More >

Hideyuki Akaza

Canadian Journal of Urology, Vol.12, Suppl.1, pp. 77-80, 2005

Abstract Two decades have passed since the concept of Maximal Androgen Blockade (MAB) was first applied to the clinical treatment of prostate cancer. The theory is that by cutting off the supply of androgen from the adrenal gland, androgen blockade of the prostate could be made more complete. However, to date the clinical benefit of MAB has failed to live up to the theoretically expected effect. Having said that, fundamental research and clinical trials in recent years do indicate that the benefit of MAB is not merely an illusion. More >

Fred Saad¹, J. Curtis Nickel², Luc Valiquette¹, Richard Casey³, Irwin Kuzmarov⁴, Mostafa Elhilali⁵

Canadian Journal of Urology, Vol.12, No.4, pp. 2745-2754, 2005

Abstract Introduction and objectives: A novel slow release formulation of alfuzosin should improve compliance by reducing dosing to one 10 mg tablet per day. The current study examined efficacy, at 9 days and 3 months, and safety of this formulation of alfuzosin in BPH patients.
Methods: ALF-X was a 3-month, non-comparative, observational study of 353 BPH patients from 39 Canadian Urology centres.
Results: At baseline (BL), mean age was 63.1±9.01 years, 92.6% of patients were Caucasian, 3.4% had a history of acute urinary retention, mean duration of the micturition disorder was 48.6±54.15 months, and mean PSA was 3.3±6.65 ng/mL.… More >

J. Curtis Nickel¹, Fred Saad²

Canadian Journal of Urology, Vol.11, No.2, pp. 2186-2193, 2004

Abstract The 2003 American Urological Association (AUA) guideline on management of benign prostatic hyperplasia (BPH) was released at the AUA annual meeting in Chicago, April 2003 and the diagnosis and treatment recommendations were published later in 2003. It is likely that the 2003 AUA guideline on the management of BPH will have a profound effect on clinical urologic practice in the USA, but its influence on Canadian urological practice will be different because of our socialized medical system, manpower issues, availability of expensive technology and our unique Canadian perspective. The authors review the 2003 AUA guideline More >

Armen G Aprikian¹, Neil Fleshner², Adrian Langleben³, Jeffrey Hames⁴

Canadian Journal of Urology, Vol.10, No.5, pp. 1986-1994, 2003

Abstract Objectives: To provide context in oncology for the significance of the benefits and cost of combined androgen blockade (CAB) in the treatment of advanced prostate cancer.
Methods: Canadian drug costs for the survival benefit with CAB in advanced prostate cancer were compared with the costs of benefit with new treatments in advanced non-small-cell lung cancer (NSCLC), metastatic colorectal cancer, and metastatic breast cancer. Clinical toxicities were also compared.
Results: The survival benefit with CAB in advanced prostate cancer appears to be approximately 3 months. The survival benefit with the addition of vinorelbine to cisplatin for the treatment of… More >

Mostafa M. Elhilali, J. Curtis Nickel

Canadian Journal of Urology, Vol.10, No.2, pp. 1799-1802, 2003

Abstract The management of lower urinary tract symptoms (LUTS) secondary to benign prostatic hyperplasia over the last decade underwent many changes. The introduction of many medical options including alpha blockers and 5 alpha reductase inhibitors provided alternatives to what used to be surgery or “watchful waiting”.
Alpha blockers evolved over the years from non specific alpha blockers to alpha 1 selective and then to alpha 1a selective with a wider acceptance due to lack of need to titrate and a better safety profile.
5 alpha reductase inhibitor (finasteride) passed through a lot of changes from being the… More >

Francois Benard

Canadian Journal of Urology, Vol.9, No.3, pp. 1571-1571, 2002

Abstract This article has no abstract. More >